Prasad Thota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Prasad Thota has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Anusha Thota
Department of Global Pharmacovigilance, Sun Pharmaceuticals Pvt. Ltd., Gurugram, Haryana, India
4 shared publicationsBikash Medhi
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 shared publicationsGyanendra Nath Singh
Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India
2 shared publicationsKalaiselvan Vivekanandan
National Coordination Centre-Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh
2 shared publicationsPhulen Sarma
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 shared publicationsShabir Sidhu
Department of Life Sciences, IKG-Punjab Technical University, Jalandhar, Punjab
2 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by AccScience Publishing in Microbes & Immunity
- Vol. 3 (2) , 025350091
Microbiological quality control of non-sterile pediatric pharmaceutical products
Pharmaceutical pediatric products—whether sterile or non-sterile—must meet the relevant microbiological quality standards to ensure safety and efficacy. During production and use, many pharmaceutical pediatric products are vulnerable to contamination from a wide range of microbial species. Young children under 5 years of age and infants are particularly vulnerable to harmful and accidental infections due to their immature immune systems and limited prior exposure to antigens. When these young children consume pharmaceutical preparations of inadequate microbiological quality, they may be exposed to serious health risks. Maintaining the safety and efficacy of non-sterile pediatric pharmaceutical products, as well as safeguarding children’s health, depends on their microbiological quality. Pharmaceutical pediatric products are widely used in India; therefore, it is essential to assess their microbiological quality and overall safety. This study examines the microbiological quality of 26 pediatric drug products. Using compendial methods, the pediatric drug products were analyzed for the presence of specified microorganisms, total yeast and mold count, and total aerobic microbial count. Based on the study’s findings, three of the pediatric drug products showed microbial contamination levels above the maximum acceptable limits specified in the Indian Pharmacopoeia. The pediatric drug products under examination did not contain the specified microorganisms, including Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. It is advised that current good manufacturing practices and appropriate hygiene measures be strictly followed when manufacturing, handling, and dispensing these products; therefore, microbial quality control is crucial to prevent contaminated products from reaching the market and to protect public health.
- 31 December 2025
- Published by AccScience Publishing in Microbes & Immunity
- Vol. 3 (2) , 025350091
Open AccessMicrobiological quality control of non-sterile pediatric pharmaceutical products
Pharmaceutical pediatric products—whether sterile or non-sterile—must meet the relevant microbiological quality standards to ensure safety and efficacy. During production and use, many pharmaceutical pediatric products are vulnerable to contamination from a wide range of microbial species. Young children under 5 years of age and infants are particularly vulnerable to harmful and accidental infections due to their immature immune systems and limited prior exposure to antigens. When these young children consume pharmaceutical preparations of inadequate microbiological quality, they may be exposed to serious health risks. Maintaining the safety and efficacy of non-sterile pediatric pharmaceutical products, as well as safeguarding children’s health, depends on their microbiological quality. Pharmaceutical pediatric products are widely used in India; therefore, it is essential to assess their microbiological quality and overall safety. This study examines the microbiological quality of 26 pediatric drug products. Using compendial methods, the pediatric drug products were analyzed for the presence of specified microorganisms, total yeast and mold count, and total aerobic microbial count. Based on the study’s findings, three of the pediatric drug products showed microbial contamination levels above the maximum acceptable limits specified in the Indian Pharmacopoeia. The pediatric drug products under examination did not contain the specified microorganisms, including Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. It is advised that current good manufacturing practices and appropriate hygiene measures be strictly followed when manufacturing, handling, and dispensing these products; therefore, microbial quality control is crucial to prevent contaminated products from reaching the market and to protect public health.
- Open Access
- 1 April 2021
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 36 (2) , 153-162
A Comparative Study of Pharmacopoeial Quality Standards and Regulations of Radiopharmaceuticals
Radiopharmaceutical preparations are the important pharmaceutical dosage forms used for the diagnosis and therapeutic purposes. Various pharmacopoeias are having methods for the quality control of these preparations in the form of monographs. Indian Pharmacopoeia (IP) also included these monographs in IP 2014 first time with the help of an experts' group on radiopharmaceutical, drawing expertise from elite stakeholder institutions and the core team of Indian Pharmacopoeia Commission. Since then, these standards are regularly updated through the IP addendum and bringing out new edition of IP. IP is a book of official methods as per Drugs and Cosmetic Act, 1940. These standards can be used in government laboratories, private laboratories, or academia in India and abroad. This review provides an overview of the journey of radiopharmaceuticals' standard setting in IP. A comprehensive comparative information of regulatory perspectives of radiopharmaceuticals in different jurisdictions such as the US, EU, and India is also presented.
- 1 April 2021
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 36 (2) , 153-162
Open AccessA Comparative Study of Pharmacopoeial Quality Standards and Regulations of Radiopharmaceuticals
Radiopharmaceutical preparations are the important pharmaceutical dosage forms used for the diagnosis and therapeutic purposes. Various pharmacopoeias are having methods for the quality control of these preparations in the form of monographs. Indian Pharmacopoeia (IP) also included these monographs in IP 2014 first time with the help of an experts' group on radiopharmaceutical, drawing expertise from elite stakeholder institutions and the core team of Indian Pharmacopoeia Commission. Since then, these standards are regularly updated through the IP addendum and bringing out new edition of IP. IP is a book of official methods as per Drugs and Cosmetic Act, 1940. These standards can be used in government laboratories, private laboratories, or academia in India and abroad. This review provides an overview of the journey of radiopharmaceuticals' standard setting in IP. A comprehensive comparative information of regulatory perspectives of radiopharmaceuticals in different jurisdictions such as the US, EU, and India is also presented.
- 12 November 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (1) , e13167
Therapeutic options for management of Hori's nevus: A systematic review
Introduction Hori's nevus is a pigmentation disorder reported mainly in middle‐aged Asian women. There is no systematic review addressing its pharmacotherapy. Materials and methods The population for our systematic review was patients with a clinical/ histological diagnosis of Hori's nevus (both sex, any age group). We screened 5 literature databases using relevant keywords. All RCTs, observational studies and case series mentioning at least one intervention and outcome of that intervention were included. Result 19 studies were included in the final systematic review from total 680 identified non‐duplicate records. Different forms of laser[alexandrite laser (QSAL and PSAL), Nd:YAG laser (QSNYL high fluence, low fluence, 532 followed by 1064 nm), Er: YAG and Nd:YAG combination, ruby laser (QSRL), CO2 laser followed by QSRL] and dermabrasion were found to be useful in treatment of Hori' nevus. Conclusion Among alexandrite lasers, PSAL is more efficacious and safe than QSAL.In case of high fluence QSNYL, hyperpigmentation rate is quite high while low fluence QSNYLrequires morenumber of treatment sessions. The combined 1064nm + 532 nm protocol is better in terms of efficacy and safety. Er:YAG + Nd:YAG combination have similar efficacy and added advantage of synergistic action and no adverse event.
- 12 November 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (1) , e13167
Therapeutic options for management of Hori's nevus: A systematic review
Introduction Hori's nevus is a pigmentation disorder reported mainly in middle‐aged Asian women. There is no systematic review addressing its pharmacotherapy. Materials and methods The population for our systematic review was patients with a clinical/ histological diagnosis of Hori's nevus (both sex, any age group). We screened 5 literature databases using relevant keywords. All RCTs, observational studies and case series mentioning at least one intervention and outcome of that intervention were included. Result 19 studies were included in the final systematic review from total 680 identified non‐duplicate records. Different forms of laser[alexandrite laser (QSAL and PSAL), Nd:YAG laser (QSNYL high fluence, low fluence, 532 followed by 1064 nm), Er: YAG and Nd:YAG combination, ruby laser (QSRL), CO2 laser followed by QSRL] and dermabrasion were found to be useful in treatment of Hori' nevus. Conclusion Among alexandrite lasers, PSAL is more efficacious and safe than QSAL.In case of high fluence QSNYL, hyperpigmentation rate is quite high while low fluence QSNYLrequires morenumber of treatment sessions. The combined 1064nm + 532 nm protocol is better in terms of efficacy and safety. Er:YAG + Nd:YAG combination have similar efficacy and added advantage of synergistic action and no adverse event.
- Open Access
- 1 March 2019
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 10 (1) , 33-34
Targeted Spontaneous Reporting on Drug Safety Alerts Issued by Pharmacovigilance Programme of India: A New Origin of Pharmacovigilance in India
- 1 March 2019
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 10 (1) , 33-34
Open AccessTargeted Spontaneous Reporting on Drug Safety Alerts Issued by Pharmacovigilance Programme of India: A New Origin of Pharmacovigilance in India
- Open Access
- 1 January 2019
- Published by Medknow in Perspectives in Clinical Research
- Vol. 10 (3) , 140-144
Pivotal role of Pharmacovigilance Programme of India in containment of antimicrobial resistance in India
Misuse of antimicrobials has become one of the grave concerns of public health. In last two decades, this has been largely contributing in the emergence of antimicrobial resistance (AMR) among all the pathogens. A 2013 report of Centres for Disease Control and Prevention, USA figured that at least 2 million people get an antibiotic-resistant infection every year and as many as 23,000 people lost their life. A multi-country survey in Southeast Asia region conducted by World Health Organization (WHO) in 2015, identified several gaps in knowledge and awareness about the optimal use of antimicrobials and AMR. Following this, the Ministry of Health and Family Welfare (MoHFW), Government of India, developed National Action Plan in the year 2017 to combat AMR. Pharmacovigilance Programme of India (PvPI) being a flagship programme of MoHFW holds the responsibility of ensuring safety of medicines used by India population and has recently identified AMR as one of the strategic priorities. This article intends to provide insights of the recent attempts and deliberate efforts made by PvPI in the containment of AMR in India and it also intends to sensitize healthcare fraternity on restricting AMR in public interest.
- 1 January 2019
- Published by Medknow in Perspectives in Clinical Research
- Vol. 10 (3) , 140-144
Open AccessPivotal role of Pharmacovigilance Programme of India in containment of antimicrobial resistance in India
Misuse of antimicrobials has become one of the grave concerns of public health. In last two decades, this has been largely contributing in the emergence of antimicrobial resistance (AMR) among all the pathogens. A 2013 report of Centres for Disease Control and Prevention, USA figured that at least 2 million people get an antibiotic-resistant infection every year and as many as 23,000 people lost their life. A multi-country survey in Southeast Asia region conducted by World Health Organization (WHO) in 2015, identified several gaps in knowledge and awareness about the optimal use of antimicrobials and AMR. Following this, the Ministry of Health and Family Welfare (MoHFW), Government of India, developed National Action Plan in the year 2017 to combat AMR. Pharmacovigilance Programme of India (PvPI) being a flagship programme of MoHFW holds the responsibility of ensuring safety of medicines used by India population and has recently identified AMR as one of the strategic priorities. This article intends to provide insights of the recent attempts and deliberate efforts made by PvPI in the containment of AMR in India and it also intends to sensitize healthcare fraternity on restricting AMR in public interest.
- Open Access
- 1 January 2018
- Published by Medknow in Perspectives in Clinical Research
- Vol. 9 (1) , 51-55
Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
Background: The National Coordination Centre-Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission works under the aegis of Ministry of Health and Family Welfare, Government of India. It promotes patient safety in India and also supports postmarketing surveillance programs. Currently, almost hundred thousand case reports are submitted to NCC-PvPI each year through its 250 ADR Monitoring Centers (AMCs) located across India, and India is the one of the top ten contributor countries under WHO-Uppsala Monitoring Centre since 2012 and start issuing drug safety alerts from March 2016. Aim: This study aims to highlight the drug safety alerts issued by NCC-PvPI from March 2016 to June 2017 and urgent need for further monitoring by adopting targeted spontaneous reporting (TSR) methodology at AMCs and its impact on the NCC's drug safety database, i.e., VigiFlow in India. Methodology: A retrospective analysis was done for the reported unlisted ADRs by various AMCs to PvPI through VigiFlow, i.e., individual case safety report (ICSR) management system at NCC, where these unlisted drug-ADR combinations considered and issued as drug safety alerts for further reporting these to NCC, if any detected at healthcare settings during routine clinical practice by healthcare professionals. Results: From July 2011 to June 2017, NCC-PvPI was collated 250,787 ICSRs and contributed to WHO international drug safety database, i.e., VigiBase, from these ICSRs; NCC-PvPI was issued 56 drug safety alerts from March 2016 to June 2017. Conclusion: In India, spontaneous reporting of ADRs existed since 1998 under passive surveillance method, but there is an urgent need to initiate TSR, which is a complementary method to spontaneous reporting on these drug safety alerts for further regulatory action by Central Drugs Standard Control Organization.
- 1 January 2018
- Published by Medknow in Perspectives in Clinical Research
- Vol. 9 (1) , 51-55
Open AccessDrug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
Background: The National Coordination Centre-Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission works under the aegis of Ministry of Health and Family Welfare, Government of India. It promotes patient safety in India and also supports postmarketing surveillance programs. Currently, almost hundred thousand case reports are submitted to NCC-PvPI each year through its 250 ADR Monitoring Centers (AMCs) located across India, and India is the one of the top ten contributor countries under WHO-Uppsala Monitoring Centre since 2012 and start issuing drug safety alerts from March 2016. Aim: This study aims to highlight the drug safety alerts issued by NCC-PvPI from March 2016 to June 2017 and urgent need for further monitoring by adopting targeted spontaneous reporting (TSR) methodology at AMCs and its impact on the NCC's drug safety database, i.e., VigiFlow in India. Methodology: A retrospective analysis was done for the reported unlisted ADRs by various AMCs to PvPI through VigiFlow, i.e., individual case safety report (ICSR) management system at NCC, where these unlisted drug-ADR combinations considered and issued as drug safety alerts for further reporting these to NCC, if any detected at healthcare settings during routine clinical practice by healthcare professionals. Results: From July 2011 to June 2017, NCC-PvPI was collated 250,787 ICSRs and contributed to WHO international drug safety database, i.e., VigiBase, from these ICSRs; NCC-PvPI was issued 56 drug safety alerts from March 2016 to June 2017. Conclusion: In India, spontaneous reporting of ADRs existed since 1998 under passive surveillance method, but there is an urgent need to initiate TSR, which is a complementary method to spontaneous reporting on these drug safety alerts for further regulatory action by Central Drugs Standard Control Organization.
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal of Psychiatry
- Vol. 59 (3) , 393-395
Pharmacovigilance in drugs used in the treatment of drug dependence
Indian J Psychiatry, Indian Journal of Psychiatry is the official publication of the Indian Psychiatric Society that considers for publication articles in all fields of Psychiatry
- 1 January 2017
- Published by Medknow in Indian Journal of Psychiatry
- Vol. 59 (3) , 393-395
Open AccessPharmacovigilance in drugs used in the treatment of drug dependence
Indian J Psychiatry, Indian Journal of Psychiatry is the official publication of the Indian Psychiatric Society that considers for publication articles in all fields of Psychiatry